Helicobacter Pylori Infection
Conditions
Keywords
Sequential Therapy, Rescue Treatment
Brief summary
The purpose of this study is to assess efficacy of a 14-day sequential therapy for the rescue treatment of refractory Helicobacter pylori infection, and whether it is safe while maintaining an ideal eradication rates.
Detailed description
Half of the world's population is infected with Helicobacter pylori. Strong evidence supports that H.pylori eradication is an effective approach to reduce the risk of developing gastric cancer. However, eradication rates of first-line therapy decreased over years due to the rapidly emerging antibiotic resistance of H. pylori worldwide. An ideal rescue therapeutic regimen to cure refractory H.pylori infection is currently warranted. Traditional sequential therapy failed to achieve an ideal eradication rates (over\>95%) as a third line treatment in the region with high antibiotic resistance. The investigator's study aims to evaluate the efficacy 14-day modified sequential therapy in the patients with two or more treatment failure, and whether the adverse effects of this new modified sequential therapy are tolerable.
Interventions
Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy for the Helicobacter pylori eradication. The regimen contains rabeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by rabeprazole，amoxicillin, tetracycline and colloidal bismuth pectin for the second 7 days.
Sponsors
Shandong University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Patients aged 18-70 with persistent H. pylori infection. * Patients failed at least three different standard eradication therapies before. Previous standard eradication therapy was defined as a 10-day or 14-day quadruple regimen designed according to Maastricht V report.
Exclusion criteria
* Patients unable or unwilling to receive gastroscopy. * Patients treated with H2-receptor antagonist, PPI, bismuth and antibiotics in the previous 4 weeks. * Patients with gastorectomy, acute GI bleeding and advanced gastric cancer. * History of allergy to any of the drugs used in the study. * Severe concomitant cardiovascular, respiratory, or endocrine diseases, clinically significant renal or hepatic disease, hematologic disorders and any other clinically significant medical condition that could increase risk. * Currently pregnant or lactating. * Severe neurologic or psychiatric disorders. * Alcohol abuse or drug addiction. * Patients with compliance lower than 90% in any previous treatment are not included. * Inability to provide informed consent and other situations that could interfere with the examination or therapeutic protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Eradication rates | 6 months | Both intention to treat(ITT) and per-protocol(PP) analyses will be used for the assessment of the eradication rates of Helicobacter pylori infection. The ITT analysis includes all randomly assigned patients who take at least one dose of the study medications. The PP analysis is limited to patients who take over 90% of the study medications and complete follow-up. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The rate of adverse events happening | 6 months | Common adverse events will be measured using a 8-point Likert scale, and patients rate their symptoms from 0 (none) to 8 (severe) during the treatment process. |
| The rate of improving dyspepsia symptoms after Helicobacter pylori eradication. | 6 months | Dyspepsia symptoms will also be measured using a 8-point Likert scale |
| The rate of good compliance | 6 months | Patients taken over 90% of drugs are considered to have a good compliance. |
Countries
China
Contacts
Primary ContactXiuli Zuo, MD,PhD
Backup ContactXiuli Zuo, MD,PhD
Outcome results
None listed